Method of producing macrolide compounds

专利摘要:
C-20 modified derivatives of tylosin and tylosin-like macrolides useful as antibiotics and as intermediates to other antibiotics.
公开号:SU1375135A3
申请号:SU833641764
申请日:1983-09-08
公开日:1988-02-15
发明作者:Дебоно Мануэль；Эндрю Кирст Герберт
申请人:Эли Лилли Энд Компани (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of macroid compounds of the general formula
 R, where A p IT p.- y
(OH M
CHjRi
 octahydroazocin-1-yl, 4-fensh1Piperidin-1-yl, hexahydroazepin-1-yl, 1-azaspiro (4,5) dec-1-yl, 1,2,3,4-tet rahidrohinolin-1-yl , 1, 2,3,4-tetra-.- hydroisoquinolin-2-yl, 1,2,3,6-tetrahydropyridin-1-yl, pyrrolidin-I-yl, azacyclotridecin-1-yl, 3-azabicyclo - (3,2,2) -non-3-yl, 1,3,3-trimethyl-6-azabicyclo (3,2, 1) oct-6-yl, cis, - and trans-3,5-dimethylpiperidine -1-yl, RI is hydrogen, hydroxyl or microcarosyloxy
2 u
TSN. -o-h -one
but
HO-0snzO axis.
sn
Svo
or .,
with antimicrobial activity.
The aim of the invention is to develop a method for producing new macrolide compounds with increased antimicrobial activity.
Example 5. 20-DN-DO-20- (Hexahydroazepin-1-yl) desmicosin 20 - DN-DO-20 - hereinafter means 20 - dihydro-20-deoxy-; Desmicosin-ACHjCHO, where R, is mikarosyloxy
RI - s.
Desmicosin (10 g, 13 mmol) dissolved in anhydrous methanol 100 ml is quickly added to a solution of sodium cyanoborohydride (3.3 g, 52 mmol) and hexamethylenimine (6.5 g, 7.5 ml, 65 mmol) in anhydrous methanol (50 ml) under nitrogen. The reaction mixture is stirred under nitrogen at room temperature for about 3 hours and then evaporated.
io
15
20 25
thirty
35
Q
d,
0
five
under reduced pressure. The resulting residue is dissolved in methylene chloride with exactly that amount of ethyl acetate to dissolve the residue, and this solution is extracted with a saturated solution of sodium bicarbonate. The organic layer is dried, dried over sodium sulfate, evaporated under reduced pressure, and a light yellow foam is obtained. This foam is purified by chromatography on silica gel, eluted first with methylene chloride (1 L), then stepwise with 500 ml portions of methylene chloride / methanol in ratios: 98: 2; 96: 4; 94: 6; 92: 8 and 9: I wil - completion, with mixtures of methylene chloride (methanol) ammonium hydroxide in ratios: 90: 10: 0.5 (500 ml) and 75:: 25: 0.5 M (2 L). The fractions containing the desired product are identified by TLC, combined and evaporated to dryness. 6.035 g (7.07 mmol) of 20-DN-DO-20 (hexahydroazepin-I-yl) desmycosin are obtained in the form of a white foam. Other fractions that contain the impure product are combined, redissolved in methylene chloride, extracted again with a saturated sodium bicarbonate solution, and purified as previously using a silica column with methylene chloride / methanol (9: 1) and elution with methylene chloride / methanol / ammonium hydroxide in the following ratios: 90: 10: 0.5 (500 ml) and 80:20: 0.5 (1 l). An additional 1.372 g (1.61 mmol) of product is obtained. The total yield of 20-DN-DO-20 - (hexahydroazepin-1-yl) desmicosin 7.407 g (8.68 mmol, 67%).
Example 2. 20-DN-DS-4- (4-Phensh1Piperidin-1-yl) desmycosin.
Desmicosin (1.5 g, 2 mmol) is dissolved in absolute methanol / 60 ml and treated with 4-phenylpiperidine (640 mg, 4 mmol) in the presence of a Linde 4A molar sieve. After 30 min, NaBHCN (500 ml, 8 mmol) was added; and the mixture is stirred for 2.5 hours at room temperature. The mixture was poured into saturated sodium bicarbonate solution (200 ml) and extracted with methylene chloride (3x200 ml). The combined extracts were dried over sodium sulfate, filtered, and ground under reduced pressure. The residue (3.6 g) was purified by express chromatography on silica gel, eluting with a gradient from 1 liter of methylene chloride to 1 liter of mrtanol / methylene chloride (5:95), then 1 liter of methanol / methylene chloride (5:95). The fractions containing the desired pro- duct are identified by TLC, combined and evaporated to dryness to obtain 680 mg of 20-DN-DO-20-4-phenylpiperidin-1-yl desmicosin.
Example 3. 20-pH-DO-20- (Hexagidroazepin -1-yl) -4-deoxidizing -
KOZIN
A solution of 4-deoxysesmicosine (565 mg, 0.75 mmol) in methanol (15 ml) in an atmosphere of argon was mixed with an activated Linde molecular sieve for 2.2 g for 30 minutes, then added hexamethylenediamine (0, 25 ml, 2.25 mmol). After 1 h, the reaction mixture is added; sodium cyanoborohydride (141 mg, 2.25 mmol). After 45 minutes, the reaction mixture was poured into saturated sodium bicarbonate solution and extracted with ethyl acetate. The combined organic extracts are shaken with a saturated solution of sodium chloride, dried over sodium sulfate, filtered, evaporated to give 600 ml of crude product. This product is purified by preparative thin layer chromatography on silica gel, eluted with a mixture of dichloromethane (methanol) and concentrated ammonium hydroxide (90:15: 2) to obtain 150 ml (yield 24%) 20-DN-DO-20 - (hexahydroazepine- 1- yl) -4, -deoxydesmicosin.
Example 4. 20-DN-DO-20 - (Oak tagidroazotsin-1-yl) desmicosin.
Desmicosin (4.0 g, 5.2 mmol) is dissolved in absolute methanol (30 ml) and treated with heptamethylene-imine (1.2 g, 1.3 ml, 10.4 mmol) and in the presence of a molecular sieve. After completion of the reaction, the mixture is stirred for 1 h at room temperature, then quickly pipetted, a solution of sodium borohydride (60 mg, 1.6 mmol) in absolute methanol (10 ml) is poured. The reaction mixture is stirred for 1.5 hours at room temperature, then another 30 mg of sodium borohydride is added (one portion as a solid). The reaction mixture is stirred for another 75 minutes and then filtered. The filtrate is evaporated under reduced pressure. The residue is dissolved in ethyl acetate (150 ml) and this solution is extracted with water (150 ml) and saturated
about
l -
five
five
sodium bicarbonate solution (100 ml). The ethyl acetate solution is then extracted with 0.5 M NaHiP04 buffer solution (150 ml) with pH 6.5. The buffer extract is evaporated in vacuo to remove the remaining ethyl acetate and then stirred rapidly with slow addition of 5N sodium hydroxide to give a thick white precipitate. The white solid is removed by filtration and dried to give 3.55 g of 20-DN-DO-20 - (octahydroazopin-1-yl) desmycosin.
Example 5. 20-DN-DO-20 - (1-Azaspiro) 4,5- (decan-1-yl) desmicosin.
Desmicosin (5.0 g, 6.5 mmol) is dissolved in absolute methanol (50 ml) and treated with 1-azaspiro (4, -5) deca- nome, 31.36 g, 9.8 mmol in the presence of a molecular sieve. . After 15 minutes, 620 ml (9.8 mmol) was added and the mixture was stirred for 17 hours at room temperature. The reaction mixture is filtered and the filtrate is evaporated under reduced pressure. The residue was dissolved in ethyl acetate (300 ml) and extracted with water (300 ml and 100 ml). Then the product is extracted from an ethyl acetate solution with 0.5 M NaH2P04 buffer with pH 6.5 (300 and 100 ml). The phosphate buffer extracts are combined and evaporated in vacuo to remove the remaining ethyl acetamide. Then the phosphate buffer solution is rapidly stirred at a slow addition of 5 n. caustic soda and get a thick white precipitate. The white solid is collected by filtration, washed with water, and dried to give 20-DN-DO-20 - (1-azaspiro) 4,5- (decan-1-yl) desmicosin (3.52 g).
Example 6. 20-DN-DO-20- (1,2, 3,4-Tetrahydroquinolin-1-yl} desmico.
ZIN.
Desmikosin (11.6 g, 15 mmol) is dissolved in dry methanol (100 ml) and 1,2,3,4-tetrahydroquinoline (3.8 ml, 30 mmol) is added. The mixture is stirred at room temperature for -. 30 minutes, and then sodium cyanoborohydride (1.25 g, 20 mmol) is added. The mixture is stirred overnight, then evaporated under reduced pressure. The residue is partitioned between ethyl acetate and water (100 ml each). The organic layer is extracted successively with aqueous phosphate buffer pH 6.5 (100 ml) and aqueous phosphorus
pH buffer with pH 4.5 (100 ml). The ethyl acetate layer was dried over sodium sulfate, filtered, and evaporated, and the residue (g) was separated by chromatography on silica gel. The column was eluted with a linear gradient of dichloromethane (4 l) and 5% methanol plus 0.5% concentrated ammonium hydroxide in dichloro- petan (4 l). The fractions containing the desired product are identified by the method of those collected, extruded to dryness and 3.4 g of the title compound are obtained.
Example. 20-DN-DO-26 - (1, 2,3,4 - Tetrahydroisoquinolin-2-nl) desmycosin.
Desmicosin (11.6 g, 15 mmol) is dissolved in dry methanol (100 ml) and 1,2,3,4 - tetrahydroisoquinoline (3.8 ml, 30 mmol) is added. After neper mixing of the mixture in sodium cyanoborohydride (1.25 g, 20 mmol) is added at room temperature for 30 minutes. The mixture is stirred overnight and then evaporated under reduced pressure. The residue is partitioned between ethyl acetate and water (150 ml each). Then the organic layer is extracted sequentially with phosphate buffer, pH 6.5 (100 ml) and phosphate buffer with pH 4.5 (100 m). The pH 4.5 phosphate buffer extract is evaporated under reduced pressure to remove ethyl acetate, after which the pH is adjusted to 10 by the addition of 5N.
356
sodium hydroxide. The precipitate formed is collected, dried in air and 5.6 g of the title compound are obtained.
Example 20-DN-DO-20 - (l, 2,3,6 - Tetrahydropyridin-1-yl) desmycosin,
Desmikosin (11.6 g, 15 mmol) is dissolved in anhydrous methanol (I00 ml) and 1,2,3,6 - tetrahydropyridine (2.8 ml, 30 mmol) is added, After stirring the mixture in a mixture of Sodium cyanoborohydride (1.25 f 20 mmol) is added at room temperature for 30 minutes. The mixture is stirred overnight, then evaporated under reduced pressure. The residue is dissolved. in ethyl acetate (150 ml). This solution is extracted with water (150 ml), then with aqueous phosphate buffer pH 6.5 (2x100 ml). Buffer solutions were boiled separately under reduced pressure to remove ethyl acetate, then adjusted to pH 10 by the addition of 5N sodium hydroxide. The resulting precipitates were collected by filtration, dried in air, and 5.4 g (first extract) and 3.2 g (second extract) of the title compound were obtained.
Other compounds were prepared in a similar manner. The values of the substituents R - R and the physicochemical properties of the compounds obtained are listed in Table 1.
111375
 Tests of antimicrobial activity. Antimicrobial activity was investigated in vivo in relation to experimentally induced infections in experimental animals. The values of ED (dose in mg / kg, providing, and protection of 50% - animals) for mice infected with Stuptococcua Pyogenes C203 are given in table 2. For comparison, Q data is given for a known drug, deamicosine.
table 2
3512
Pasteurella infections in those infected with subcutaneous injection of 0.1 ml of 10 - diluted tryptosis-broth culture of bacteria. In this case, without the introduction of the drug, the number of deaths was 100% (10 deaths per 10 treated cells) within 24 hours. In the experiments, the preparations were injected subcutaneously at a dose of 30 mg / kg 1 and 4 hours after infection, or as an aqueous solution ( 2 g / gallon) 4–20 hours before spraying and within 3 days after. The test results are given in
The antimicrobial activity against negative bacteria was tested in vivo against
55 17 - 94.5 mg / kg. As can be seen from the data table. 2 and 3, the effectiveness of compounds 1-19 under optimal conditions is much higher than that of the known pre-1313751
parata (compounds 15, 17 and 18 in table 2 when given subcutaneously, all compounds in table 2 when orally administered, compounds 5, 7, I, 12, 13, 14, 16 in table 3). Thus, the proposed compounds provide an increase in antimicrobial activity.

权利要求:
Claims (1)
[1]
Invention Formula d
The method of obtaining macrolide compounds of the general formula
ACHjCHjR,
where is -
p it is 0 - VC
.
Chjft
R - octahydroazocin-1-yl, 4-phenylpiperidin-1-yl, hexahydroazepin-1-yl, 1-azaspiro (4,5) dec-1-yl, 1,2,3,4-tetrahydroquinolin-1- yl, 1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,6-tetrahydropyridin-1-yl, pyrrolidin-1-yl, azacyclotridedecin-1-yl, 3-azabi- cyclo (3,2,2) -non-3-yl, 1,3,3-trime 351A
tyl-6-azabicyclo (3,2,1) oct-6-yl, cis-and trans-3,5-dimethylpiperidin-1-yl,
R is hydrogen, hydroxyl, or microsyloxy.
g
-OH VoH
.
or
20
It is similar in that the aldehyde of the formula
ACHjCH
ABOUT,
where A has the indicated meanings, sodium borohydride or sodium cyanoborohydride in the presence of an amine of the general formula
RH,
where R has the indicated meanings, in medium C, -C4. - alkanoyl at room temperature.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1375135A3|1988-02-15|Method of producing macrolide compounds

---

Fleet et al.1987|Synthesis of deoxymannojirimycin fagomine deoxynojirimycin 2-acetamido-1, 5-imino-1, 2, 5-trideoxy-D-mannitol 2-acetamido-1, 5-imino-1, 2, 5-trideoxy-D-glucitol 2S, 3R, 4R, 5R-trihydroxypipecolic acid and 2S, 3R, 4R, 5S-trihydroxypipecolic acid from methyl 3-O-benzyl-2, 6-dideoxy-2, 6-imino-α-D-mannofuranoside

---

US3803124A|1974-04-09|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives

---

CA2184734C|1999-08-03|3''-desmethoxy derivatives of erythromycin and azithromycin

---

US4345069A|1982-08-17|Deformyltylosin derivatives

---

EP0001841B1|1982-12-01|Tylosin derivatives

---

US4921947A|1990-05-01|Process for preparing macrolide derivatives

---

US4065615A|1977-12-27|Deoxyaminoglycoside antibiotic derivatives

---

CA1229336A|1987-11-17|C-20-modified macrolide derivatives

---

KR860001282B1|1986-09-05|Method of preparing c-20-and c-23-modified derivatives

---

US4847242A|1989-07-11|11-ether derivatives of erythromycins

---

US4268665A|1981-05-19|Derivatives of antibiotic tylosin

---

EP0262904A2|1988-04-06|Modifications of mycinose and 3-0-demethylmycinose in tylosintype macrolides

---

SU1579465A3|1990-07-15|Method of obtaining 4ъ-haloid-anthracycling licosides

---

Argoudelis et al.1965|Studies on the Biosynthesis of Lincomycin. II. Antibiotic U-11,973, N-Demethyl Lincomycin

---

SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides

---

EP1399458B1|2005-08-03|An arylation method for the functionalization of o-allyl erythromycin derivatives

---

GB1576085A|1980-10-01|Rubradirin derivatives

---

DE2361159A1|1974-06-20|3'-DEOXY DERIVATIVES OF NEAMINE, ITS RELATED AMINOGLYCOSIDIC ANTIBIOTICS AND THEIR PRODUCTION

---

US4242504A|1980-12-30|3"-Acylated macrolide antibiotics

---

US3904597A|1975-09-09|Antibiotic derivatives

---

EP0262905A2|1988-04-06|Modifications of 3-0-demethyl-mycinose in macrocin and lactenocin

---

US4252972A|1981-02-24|Fortimicin B-1,2:4,5-bis-carbamates

---

CA1098123A|1981-03-24|Semi-synthetic 4"-sulfonylamino-oleandomycin derivatives

---

US4008218A|1977-02-15|1-N-|-α-substituted-ω-aminoacyl)-neamine or -ribostamycin and the production thereof

同族专利:

---

公开号 | 公开日

---

CS665383A2|1988-04-15|

---

NL950001I2|1997-05-01|

---

NZ205501A|1985-09-13|

---

LU90240I2|1998-07-06|

---

ES8607336A1|1986-06-01|

---

AU561147B2|1987-04-30|

---

KR850000961B1|1985-07-02|

---

JPS5973598A|1984-04-25|

---

PL142251B1|1987-10-31|

---

FI833229A0|1983-09-09|

---

PH23242A|1989-06-06|

---

DK413783A|1984-03-14|

---

CY1417A|1988-04-22|

---

EG16287A|1987-04-30|

---

RO89235A|1986-03-15|

---

UA6045A1|1994-12-29|

---

PL243718A1|1985-04-09|

---

HU194271B|1988-01-28|

---

ES525544A0|1986-02-01|

---

AU1871083A|1984-03-22|

---

NL950001I1|1995-02-16|

---

BG42675A3|1988-01-15|

---

CA1243310A|1988-10-18|

---

AR241595A1|1992-09-30|

---

GR79067B|1984-10-02|

---

ES8604596A1|1986-02-01|

---

FI833229A|1984-03-14|

---

GB2127017A|1984-04-04|

---

PL142304B1|1987-10-31|

---

FI73222B|1987-05-29|

---

ATA320683A|1986-04-15|

---

JPH021840B2|1990-01-12|

---

DK153555B|1988-07-25|

---

EP0103465A1|1984-03-21|

---

KR840005734A|1984-11-15|

---

IL69666D0|1983-12-30|

---

HUT35272A|1985-06-28|

---

HK21888A|1988-03-31|

---

MY8700756A|1987-12-31|

---

FI73222C|1987-09-10|

---

IL69666A|1987-10-20|

---

PL250619A1|1985-07-30|

---

DE3366097D1|1986-10-16|

---

IE832131L|1984-03-13|

---

PT77335B|1986-05-19|

---

EP0103465B1|1986-09-10|

---

ZA836741B|1984-04-25|

---

DK153555C|1988-12-05|

---

DK413783D0|1983-09-12|

---

IE55916B1|1991-02-27|

---

AT381707B|1986-11-25|

---

GB2127017B|1986-01-15|

---

ES548472A0|1986-06-01|

---

CS259862B2|1988-11-15|

---

DD210284A5|1984-06-06|

---

PT77335A|1983-10-01|

---

GB8324044D0|1983-10-12|

---

SG99287G|1988-09-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

RU2478630C2|2007-12-07|2013-04-10|ЭЙСАН Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД.|Intermediate compounds and methods for preparing zearalene macrolide analogues|IE32839B1|1967-12-04|1973-12-28|Lilly Co Eli|Urea-antibiotic adducts and process for preparing the same|

---

US4279896A|1980-06-23|1981-07-21|Schering Corporation|Novel 20-imino macrolide antibacterial agents|

---

JPH0142277B2|1982-02-25|1989-09-11|Satoshi Oomura|JPH0526797B2|1983-03-30|1993-04-19|Satoshi Oomura|

---

US4921947A|1986-03-31|1990-05-01|Eli Lilly And Company|Process for preparing macrolide derivatives|

---

EP0262903A3|1986-09-29|1988-11-02|Eli Lilly And Company|New acyl derivatives of 20-modified tylosin and desmycosin compounds|

---

US4820694A|1986-09-29|1989-04-11|Eli Lilly And Company|Modifications of 3-O-demethylmycinose in macrocin and lactenocin|

---

US5354708A|1992-06-04|1994-10-11|Taskar Nikhil R|Method of nitrogen doping of II-VI semiconductor compounds during epitaxial growth using an amine|

---

TW226373B|1992-07-15|1994-07-11|Pfizer|

---

ES2076107B1|1993-09-20|1996-04-01|Pfizer|DERIVATIVES OF MACROLID ANTIBIOTICS OF RINGS OF 16 MEMBERS.|

---

AU3121095A|1994-09-22|1996-04-09|Pfizer Inc.|Antibiotic macrolides|

---

EP0778283A3|1995-12-05|1998-01-28|Pfizer Inc.|Antibiotic macrolides|

---

US6605599B1|1997-07-08|2003-08-12|Bristol-Myers Squibb Company|Epothilone derivatives|

---

TW565452B|1998-03-02|2003-12-11|Lilly Co Eli|A pharmaceutical composition for use in inhibiting swine infertility and respiratory syndrome virusproliferation in swine in need of treatment|

---

KR101538599B1|2006-07-28|2015-07-21|인터벳 인터내셔널 비.브이.|Macrolide synthesis process|

---

EP2019112A1|2007-07-26|2009-01-28|Intervet International BV|Macrolide solid-state forms|

---

PT2999707T|2013-05-23|2018-05-23|Kitasato Inst|Tylosin derivatives and method for preparation thereof|

---

CN103880903B|2014-03-21|2016-06-15|烟台万润药业有限公司|A kind of preparation method of tylosin class macrolide and derivant thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US41724782A| true| 1982-09-13|1982-09-13|

---